Astellas Pharma (OTCMKTS:ALPMY) Reaches New 12-Month High – Still a Buy?

Astellas Pharma Inc. (OTCMKTS:ALPMY) shares hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $15.40 and last traded at $15.37, with a volume of 147490 shares traded. The stock had previously closed at $14.11.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Citigroup lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Monday, January 19th. Zacks Research downgraded Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 22nd. Three research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Hold”.

Astellas Pharma Price Performance

The business has a fifty day moving average price of $13.62 and a 200 day moving average price of $11.98. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.03 and a quick ratio of 0.80. The company has a market capitalization of $27.81 billion, a price-to-earnings ratio of 32.70 and a beta of 0.18.

About Astellas Pharma

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).